PMV PHARMACEUTICALS INC's ticker is PMVP and the CUSIP is 69353Y103. A total of 107 filers reported holding PMV PHARMACEUTICALS INC in Q4 2021. The put-call ratio across all filers is - and the average weighting 1.0%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q2 2024 | $1,310,165 | -29.6% | 808,744 | -26.2% | 0.00% | – |
| Q1 2024 | $1,861,925 | -25.2% | 1,095,250 | +36.4% | 0.00% | – |
| Q4 2023 | $2,488,912 | -57.0% | 802,875 | -14.9% | 0.00% | -100.0% |
| Q3 2023 | $5,793,035 | +44.8% | 943,491 | +47.6% | 0.00% | 0.0% |
| Q2 2023 | $4,000,421 | +28.3% | 639,045 | -2.2% | 0.00% | 0.0% |
| Q1 2023 | $3,117,820 | -41.1% | 653,631 | +7.5% | 0.00% | 0.0% |
| Q4 2022 | $5,289,165 | +84324.0% | 607,950 | +15.5% | 0.00% | -50.0% |
| Q3 2022 | $6,265 | -7.8% | 526,464 | +10.4% | 0.00% | 0.0% |
| Q2 2022 | $6,796 | -99.9% | 476,934 | +14.1% | 0.00% | 0.0% |
| Q1 2022 | $8,703,000 | +51.1% | 418,045 | +67.7% | 0.00% | +100.0% |
| Q4 2021 | $5,758,000 | -34.2% | 249,242 | -15.2% | 0.00% | -50.0% |
| Q3 2021 | $8,756,000 | +65.0% | 293,840 | +89.1% | 0.00% | +100.0% |
| Q2 2021 | $5,307,000 | +99.6% | 155,377 | +92.2% | 0.00% | 0.0% |
| Q1 2021 | $2,659,000 | -55.3% | 80,861 | -51.8% | 0.00% | -50.0% |
| Q3 2020 | $5,955,000 | – | 167,751 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Euclidean Capital LLC | 4,179,416 | $257,076,000 | 54.42% |
| INTERWEST VENTURE MANAGEMENT CO | 6,469,911 | $397,964,000 | 49.71% |
| Octagon Capital Advisors LP | 250,000 | $15,378,000 | 5.33% |
| Boxer Capital, LLC | 2,268,236 | $139,519,000 | 4.48% |
| COMMODORE CAPITAL LP | 125,000 | $7,689,000 | 4.18% |
| Orbimed Advisors | 7,330,423 | $450,894,000 | 3.95% |
| Asymmetry Capital Management, L.P. | 96,595 | $5,942,000 | 2.71% |
| Avoro Capital Advisors LLC | 2,350,267 | $130,536,000 | 2.25% |
| RA Capital Management | 1,710,265 | $105,198,000 | 1.47% |
| HighVista Strategies LLC | 22,654 | $1,393,000 | 0.89% |